Analyst firms · Barclays · CNC
Barclays CNC price target and rating history
Centene Corporation (CNC) · Health Care
Barclays rates Centene Corporation (CNC) Overweight with a $54 price target, as of its latest action on Jan 5, 2026. It has published 5 rating actions on CNC since January 2022, including 1 upgrade and 1 downgrade. Across 6 firms with a CNC price target in the last 12 months, the median target is $65. Barclays's $54 is 17% below that.
- Current rating
- Overweight
- Price target
- $54
- Median target, all firms
- $65
- Actions on CNC
- 5
Barclays price target on CNC
Every Barclays rating on CNC
- Jan 5, 2026
- Jun 2, 2025
- Mar 6, 2024
- Jul 28, 2022
- Jan 7, 2022
How other firms rate CNC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Buy | $80 | Aug 11, 2026 |
| RBC Capital Markets | Sector Perform | $70 | Jun 23, 2026 |
| Deutsche Bank | Buy | $80 | May 20, 2026 |
| Cantor Fitzgerald | Overweight | $60 | Apr 29, 2026 |
| BofA Securities | Buy | $60 | Apr 29, 2026 |
| Barclays | Overweight | $54 | Jan 5, 2026 |
Questions about Barclays and CNC
- What is Barclays's price target for CNC?
- Barclays's latest stated price target for Centene Corporation (CNC) is $54, from its action on Jan 5, 2026.
- What is Barclays's rating on CNC?
- Barclays rates CNC Overweight, a bullish rating, as of Jan 5, 2026.
- When did Barclays last change its view on CNC?
- On Jan 5, 2026, Barclays upgrades to Overweight from Equal Weight, price target $54.
- How does Barclays's CNC target compare with other analysts?
- Across 6 firms with a CNC price target in the last 12 months, the median target is $65. Barclays's $54 is 17% below that.
More CNC rating histories
- Argus Research3
- Deutsche Bank3
- Cantor Fitzgerald3
- BofA Securities5
- Wells Fargo5
- Morgan Stanley7
- UBS3
- Jefferies4
- Credit Suisse4
All Barclays ratingsCNC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.